History of U.S. military contributions to the study of viral hepatitis

Military Medicine

Volumn 170, Issue 4 SUPPL., 2005, Pages 71-76

  Dooley, David P ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS E VACCINE; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONVALESCENCE; EPIDEMIC; EXERCISE; GENE SEQUENCE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS E; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPROPHYLAXIS; INFECTIOUS HEPATITIS; JAUNDICE; MILITARY MEDICINE; UNITED STATES; VIRUS HEPATITIS; VIRUS ISOLATION; VIRUS TRANSMISSION;

EID: 17444392830     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.170.4S.71     Document Type: Conference Paper

References (65)

1. Reuben A: The thin red line. Hepatology 2002; 36: 770-3.
2. Havens WP: Viral hepatitis. Yale J Biol Med 1961; 34: 314-28.
3. Greene RC: The epidemics that delayed D-Day. Nurs RSA 1987; 2: 24-5.
4. Freeman G: Epidemiology and incubation period of jaundice following yellow fever vaccination. Am J Trop Med 1946; 26: 15-32.
5. Norman JE, Beebe GW, Hoofnagle JH, Seeff LB: Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology 1993; 18: 790-7.
6. Kirk R: Spread of infective hepatitis. Lancet 1945; 1: 80-1.
7. Havens WP: Infectious hepatitis. Medicine 1948; 27: 279-326.
8. Paul JR, Gardner HT: Endemiologic aspects of hepatitis in U.S. troops in Germany 1946-1950. Am J Med 1950; 8: 565-80.
9. Swift WE, Gardner HT, Moore DJ, Streitfeld FH, Havens WP: Clinical course of viral hepatitis and the effect of exercise during convalescence. Am J Med 1960; 8: 614-22.
10. Barker MH, Capps RB, Allen FW: Chronic hepatitis in the Mediterranean theater: a new clinical syndrome. JAMA 1945; 129: 653-9.
11. Barker MH, Capps RB, Allen FW: Acute infectious hepatitis in the Mediterranean theater: including acute hepatitis without jaundice. JAMA 1945; 128: 997-1003.
12. Gauld RL: Epidemiological field studies of infectious hepatitis in the Mediterranean theater of operations. I. Clinical syndrome, morbidity, mortality, seasonal incidence. Am J Hyg 1946; 43: 248-54.
13. Gauld RL: Epidemiological field studies of infectious hepatitis in the Mediterranean theater of operations. III. Selection among American troops: age. Am J Hyg 1946; 43: 273-82.
14. Evans AS: Serum hepatitis in U.S. troops in Germany. Proc Soc Exp Biol Med 1950; 75: 809-11.
15. Stokes J, Maris EP, Gellis SS: Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum γ-globulin (human immune serum globulin) in the prophylaxis and treatment of measles. J Clin Invest 1944; 23: 510-30.
16. Havens WP: Period of infectivity of patients with experimentally induced infectious hepatitis. J Exp Med 1946; 83: 251-8.
17. Neefe JR, Baty JB, Reinhold JG, Stokes J: Inactivation of the virus of infectious hepatitis in drinking water. Am J Public Health 1947; 37: 365-72.
18. Havens WP, Ward R, Drill VA, Paul JR: Experimental production of hepatitis by feeding icterogenic materials. Proc Soc Exp Biol Med 1944; 57: 206-8.
19. Havens WP: Experiment in cross immunity between infectious hepatitis and homologous serum jaundice. Proc Soc Exp Biol Med 1945; 59: 148-50.
20. Havens WP: Immunity in experimentally induced infectious hepatitis. J Exp Med 1946; 84: 403-6.
21. Neefe JR, Gellis SS, Stokes J: Homologous serum hepatitis and infectious (epidemic) hepatitis: studies in volunteers bearing on immunological and other characteristics of the etiological agents. Am J Med 1946; 1: 3-22.
22. Gauld RL: Field studies relating to immunity in infectious hepatitis and homologous serum jaundice. Am J Public Health 1947; 37: 400-6.
23. Stokes J, Neefe FR: The prevention and attenuation of infectious hepatitis by γ-globulin. JAMA 1945; 127: 144-5.
24. Gellis SS, Stokes J, Brother GM, et al: The use of human immune serum globulin (γ-globulin) in infectious (epidemic) hepatitis in the Mediterranean theater of operations. 1. Studies on prophylaxis in two epidemics of infectious hepatitis. JAMA 1945; 128: 1062-3.
25. Stokes J, Farquhar JA, Drake ME, Capps RB, Ward CS: Length of protection by immune serum globulin (γ-globulin) during epidemics. JAMA 1951; 147: 714-9.
26. Krugman S, Giles JP, Hammond J: Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967; 200: 365-73.
27. Krugman S, Ward R, Giles JP, Jacobs AM: Infectious hepatitis: studies on the effect of γ-globulin and on the incidence of inapparent infection. JAMA 1960; 174: 823-30.
28. Chalmers TC, Eckhardt RD, Reynolds WE, et al: The treatment of acute infectious hepatitis: controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J Clin Invest 1955; 34: 1163-235.
29. Repsher LH, Freebern RK: Effects of early and vigorous exercise on recovery from infectious hepatitis. N Engl J Med 1969; 281: 1393-6.
30. Blumberg BS, Alter HJ, Visnich S: A "new" antigen in leukemia sera. JAMA 1965; 191: 541-6.
31. Prophylactic gamma globulin for prevention of endemic hepatitis: effects of U.S. gamma globulin upon the incidence of viral hepatitis and other infectious diseases in U.S. soldiers abroad. Arch Intern Med 1971; 128: 723-38.
32. Conrad ME, Lemon SM: Prevention of endemic icteric viral hepatitis by administration of Immune serum γ-globulin. J Infect Dis 1987; 156: 56-63.
33. Wenzel RP, Le Bouvier GL, Beam WE: Drug abuse and viral hepatitis in Marines. JAMA 1972; 220: 707-9.
34. Wenzel RP, Adams JF, Smith EP: Patterns of illicit drug use in viral hepatitis patients. Milit Med 1973; 138: 345-50.
35. Allen AM, Irwin GR, Karwacki JJ, Warren DC, Levine RS: Epidemic hepatitis B: a sustained outbreak in a large military population. Am J Epidemiol 1975; 102: 545-52.
36. Cates W, Warren JW: Hepatitis B in Nuremburg, Germany: epidemiology of a drug associated epidemic among U.S. Army soldiers. JAMA 1975; 234: 930-4.
37. Cowari DN, Prier RE: Changes in hepatitis morbidity in the United States Army, Europe. Milit Med 1984; 149: 260-5.
38. Brewer TG, Oetgen WJ, Dunn MA, Johnson LF: Hepatitis B in United States soldiers in Korea. South Med J 1980; 73: 1568-9.
39. Gardner LI, Redfield RR, Lednar WM, Lemon SM, Miller RN: Occupational and geographic risk factors for hepatitis B among U.S. Army enlisted personnel during 1980. Am J Epidemiol 1986; 123: 464-72.
40. Aronson NE, Palmer BF: Acute viral hepatitis in American soldiers in Korea. South Med J 1988; 81: 949-51.
41. Hyams KC, Palinkas LA, Burr RG: Viral hepatitis in the U.S. Navy, 1975-1984. Am J Epidemiol 1989; 130: 319-26.
42. Hawkins RE, Malone JD, Cloninger LA, et al: Risk of viral hepatitis among military personnel assigned to U.S. Navy ships. J Infect Dis 1992; 165: 716-9.
43. Hyams KC, Krogwold RA, Brock S, Wignall FS, Cross E, Hayes C: Heterosexual transmission of viral hepatitis and cytomegalovirus infection among United States military personnel stationed in the western Pacific. Sex Transm Dis 1993; 20: 36-40.
44. Stout RW, Mitchell SB, Parkinson MD, et al: Viral hepatitis in the U.S. Air Force, 1980-89: an epidemiological and serological study. Aviat Space Environ Med 1994; 65(Suppl 5): A66-A70.
45. Irwin GR, Allen AM, Bancroft WH, et al: Hepatitis B antigen in saliva, urine, and stool. Infect Immun 1975; 11: 142-5.
46. Bancroft WH, Snitbhan R, Scott RM, et al: Transmission of HBV to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis 1977; 135: 79-85.
47. Provost PJ, Hilleman MR: Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979; 160: 213-221.
48. Lemon SM, Binn LN: Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148: 1033-9.
49. Binn LN, Bancroft WH, Lemon SM, et al: Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J Infect Dis 1986; 153: 749-56.
50. Sjogren MH, Hoke CH, Binn LN, et al: Immunogenicity of an inactivated hepatitis A vaccine. Ann Intern Med 1991; 114: 470-1.
51. Hoke CH, Binn LN, Egan JE, et al: Hepatitis A in the U.S. Army: epidemiology and vaccine development. Vaccine 1992; 10(Suppl 1): S75-9.
52. Werzberger A, Mensch B, Kuter B, et al: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-7.
53. Innis BL, Snitbhan R, Kunasol P, et al: Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271; 1328-34.
54. Clemens R, Safary A, Hepburn A, Roche C, Standbury WJ, Andre FE: Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl 1): S44-9.
55. Ticehurst J, Popkin TJ, Bryan JP, et al: Association of hepatitis E virus with an outbreak of hepatitis in Pakistan: serologic responses and pattern of virus excretion. J Med Virol 1992; 36: 84-92.
56. Burans JP, Sharp T, Wallace M, et al: Threat of hepatitis E virus infection in Somalia during Operation Restore Hope. Clin Infect Dis 1994; 18: 100-2.
57. Clayson ET, Vaughn DW, Innis BL, Shrestha MP, Pandey R, Malla DB: Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. J Med Virol 1998; 54: 178-82.
58. Drabick JJ, Gambel JM, Gouvea VS, et al: A cluster of acute hepatitis E infection in United Nations Bangladeshi peacekeepers in Haiti. Am J Trop Med Hyg 1997; 57: 449-54.
59. Bryan JP, Iqbal M, Tsarev S, et al: Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan. Am J Trop Med Hyg 2002; 67: 662-8.
60. Clayson ET, Myint KS, Snitbhan R, et al: Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 1995; 172: 927-33.
61. Clayson ET, Innis BL, Myint KS, et al: Detection of hepatitis E virus infection among domestic swine in the Kathmandu Valley of Nepal. Am J Trop Med Hyg 1995; 53: 228-32.
62. He J, Innis BL, Shrestha MP, et al: Evidence that rodents are a reservoir of hepatitis E virus for humans in Nepal. J Clin Microbiol 2002; 40: 4493-8.
63. Gouvea V, Snellings N, Popek MJ, Longer CF, Innis BL: Hepatitis E virus: complete genome sequence and phylogenetic analysis of a Nepali isolate. Virus Res 1998; 57: 21-6.
64. Gouvea V, Hoke CH, Innis BL: Genotyping of hepatitis E virus in clinical specimens by restriction endonuclease analysis. J Virol Methods 1998; 70: 71-8.
65. He J, Hayes CG, Binn LN, et al: Hepatitis E virus DNA vaccine elicits immunologic memory in mice. J Biomed Sci 2001; 8: 223-6.